A monoclonal antibody directed at the epidermal growth factor receptor (EGFR), cetuximab [13], has been approved by the U.S. Food and Drugs Administration for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. The gene discussed is EGFR; the disease is colorectal cancer.